RB1 and breast cancer: We hypothesized that inhibition of CDK4/6 would protect normal cells with an intact G1 restriction checkpoint (Rb1 competent) from Mps1 inhibitor-associated toxicities while remaining cytotoxic to tumor cells, such as basal-a breast cancer, which have lost the checkpoint.